Drug Database
Back to search

Belgium· BE-AMP-SAM289502-00

Luminity 150 µl/ml

A perflutren, phospholipid-mikrosphären product containing perflutren, registered in Belgium by Lantheus EU. The same ATC class is registered in 9 of our 19 countries.

ATC V08DA04

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedLuminity 150 µl/mlATCV08DA04REGISTER NO.BE-AMP-SAM289502-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about perflutrenAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Perflutren, phospholipid-mikrosphären is registered in 9 of 19 countries.

Countries holding a registration under ATC V08DA04 (perflutren, phospholipid-mikrosphären), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 5 of them publish a price we can compare per daily dose
Search perflutren, phospholipid-mikrosphären products by name

Perflutren, phospholipid-mikrosphären · ATC V08DA04

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Perflutren
Manufacturer
Lantheus EU
Country
Belgium (BE)
ATC code
V08DA04
ATC class
Perflutren, Phospholipid-Mikrosphären
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

159 interactions on record for perflutren, phospholipid-mikrosphären.

Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check perflutren, phospholipid-mikrosphären against other medicinesHow interaction checks work

Perflutren, phospholipid-mikrosphären · interactions on record

159 records

  • 36 severe
  • 121 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Perflutren, phospholipid-mikrosphären in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All perflutren, phospholipid-mikrosphären products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Optison
  • Iceland · Optison
  • Liechtenstein · Optison
  • Norway · Optison

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6989dfe2-efdb-417b-8302-30416d2dc03b
GET /v1/drugs/6989dfe2-efdb-417b-8302-30416d2dc03b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Gas and solvent for dispersion for injection/infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Luminity 150 µl/ml",
  "name_fr": "Luminity 150 µl/ml",
  "name_nl": "Luminity 150 µl/ml",
  "amp_code": "SAM289502-00",
  "strengths": [
    "2.6790"
  ],
  "pack_count": 2,
  "substances": [
    "Perflutren",
    "Dipalmitoyl Glycero Phosphatidic Acid Sodium Salt (DPPA)",
    "Disodium Hydrogen Phosphate Heptahydrate",
    "Glycerol",
    "Propylene Glycol",
    "Sodium Chloride",
    "Sodium Dihydrogen Phosphate Monohydrate",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Perflutren, Phospholipid Microspheres",
  "authorisation_numbers": [
    "EU/1/06/361/002",
    "EU/1/06/361/001"
  ]
}
API referenceMCP serverPlans

See everything about perflutren, phospholipid-mikrosphären.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console